GreenLight Biosciences (GRNA) Stock Price, News & Analysis

Company Overview

FUNR manufactures and sells all-natural juice beverages. Its products include pomegranate cranberry, wild berry and passion fruit-orange. The company was founded by Alex C. Procopio on July 22, 1980 and is headquartered in Las Vegas, NV.

Key Stats

• Today's Range: $0.30 to $0.30
• 50-Day Range: $0.30 to $0.30
• 52-Week Range: $0.18 to $5.90
• Volume: 732 shs
• Average Volume: 486,986 shs
• Market Capitalization: $45.43 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

GRNA Stock Analysis - Frequently Asked Questions

What other stocks do shareholders of GreenLight Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some other companies that GreenLight Biosciences investors own include Sangamo Therapeutics (SGMO), Anavex Life Sciences (AVXL), Abrdn Asia-Pacific Income Fund (FAX), MSP Recovery (LIFW), MSP Recovery (LIFW), Meta Platforms (META) and NVIDIA (NVDA).

Company Calendar

• Today: 5/15/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biological products, except diagnostic
• Sub-Industry: N/A
• Current Symbol: NASDAQ:GRNA
• CIK: 1822691
• Web: www.eiacorp.com
• Phone: (760) 809-8079
• Fax: N/A
• Employees: 280
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): ($1.14)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-167,050,000.00
• Net Margins: -1,521.00%
• Pretax Margin: -1,510.44%
• Return on Equity: -374.26%
• Return on Assets: -122.78%

Debt

• Debt-to-Equity Ratio: 0.49
• Current Ratio: 1.21
• Quick Ratio: 1.21

Sales & Book Value

• Annual Sales: $10.20 million
• Price / Sales: 4.45
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.32 per share
• Price / Book: 0.94

Miscellaneous

• Outstanding Shares: 151,681,000
• Free Float: 105,722,000
• Market Cap: $45.43 million
• Optionable: Not Optionable
• Beta: 1.44